China National Biotec Group Company Ltd (CNBG) has announced a strategic partnership with its parent company, Sinopharm. The collaboration aims to advance the integration of the “medical science, medical industry, and medical business” industries and to explore a high-quality sustainable development model that encompasses the entire industrial chain and ecosystem.
Enhancing Product Lifecycle and Industry Chain Ecosystem
Under the partnership, CNBG will supply Sinopharm with high-quality products and services, enhancing the integration of Sinopharm into CNBG’s product lifecycle and industry chain biosphere. This collaboration will cover a range of areas, including vaccines, blood products, medical beauty products, and diagnostic reagents, among others.
Collaboration on Diverse Medical Fields
The partnership will leverage the strengths of both companies to drive innovation and development in the medical sector. By working together on vaccines, blood products, and other medical products, CNBG and Sinopharm aim to create a comprehensive approach to healthcare that benefits from the synergy of their combined expertise.-Fineline Info & Tech
